本帖最后由 老马 于 2012-1-13 21:20 编辑 0 p; U8 G/ X* \4 W 
' k- ?/ r1 z, y/ ?! X+ L 
爱必妥和阿瓦斯丁的比较9 a9 I& K& t4 }+ R2 K1 Z& z 
 
 
. W% |4 L0 B& m) O+ r* f3 t. _: V0 thttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/9 O( w: ?. M* X: G  C2 | 
 
 
8 A6 O7 P+ y7 L4 q3 N
 
) Q' ~% R6 `  ?" P0 J8 Y2 _ 
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ 
  W+ J+ ?* h4 O" H! \1 z==================================================8 A# _3 N/ z) Z* l3 j6 y 
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 
2 @, ~6 F/ S9 g8 r- A# O- b' E5 DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 F+ o; _1 H( S1 o 
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.0 H+ L$ @: p5 t5 ` 
 
 |